Table 4.

Spearman correlation analyses between PCSK9 and platelet reactivity parameters according to diabetes status and P2Y₁₂ inhibitor stratification

	Whole cohort (n = 1027)		DM (n = 277)		Non-DM (n = 750)
	r	P	r	P	r	P
Ticagrelor	n = 563		n = 143		n = 420
MPA at 7 days	0.144	0.012	0.236	0.041	0.111	0.094
MAADP at 7 days	0.080	0.228	0.336	0.013	0.033	0.664
Clopidogrel	n = 464		n = 134		n = 330
MPA at 7 days	0.100	0.113	− 0.078	0.586	0.190	0.110
MAADP at 7 days	− 0.048	0.546	− 0.172	0.160	− 0.041	0.667

PCSK9 proprotein convertase subtilisin/kexin type 9, DM diabetes mellitus, Non-DM non-diabetes mellitus, MPA maximal platelet aggregation, MA_ADP maximum amplitude of adenosine diphosphate-induced platelet-fibrin clots